Brind.
  1. Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.

NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.

1 report, 1 independent Updated Aug 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

NeoGenomics wins a patent lawsuit and submits a product for clinical reimbursement coverage.

Who's involved

What this event is mainly about
NeoGenomicsNatera

Keep exploring

Part of

Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStoryWhy Is NeoGenomics (NEO) Stock Soaring Today Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 22.5% in the morning session after a court ruled in the company's favor in